


Powered by the Sharekhan 3R Research Philosophy



# What has changed in 3R MATRIX Old New RS ↑ RQ ↔ RV ↓


#### **Company details**

Market cap:	Rs. 1,85,764 cr
52-week high/low:	Rs. 6,443 / 4,120
NSE volume: (No of shares)	3.8 lakh
BSE code:	540005
NSE code:	LTIM
Free float: (No of shares)	9.3 cr

# Shareholding (%)

Promoters	68.7
FII	8.1
DII	12.9
Others	10.4

#### **Price chart**



#### Price performance

(%)	1m	3m	6m	12m
Absolute	2.4	20.4	22.3	46.7
Relative to Sensex	2.4	12.7	14.9	28.8
Sharekhan Rese	arch Rlo	omhora		

# **LTIMindtree Ltd**

# Near term headwinds, downgrade to Hold

IT & ITES		Share	ekhan code: LTIM	
Reco/View: Hold	$\downarrow$	CMP: <b>Rs. 6,278</b>	Price Target: <b>Rs. 6,660</b>	<b>1</b>
1	Upgrade	↔ Maintain	Downgrade	

#### Summary

- LTIMindtree reported revenues at \$1084, up 0.7%/3.5% q-o-q and y-o-y respectively in constant currency (CC), which was largely in line with our estimates of 0.9% q-o-q CC revenue growth, impacted by higher and wider than expected furloughs.
- EBIT margins declined ~60 bps q-o-q to 15.4% due to furloughs, lower working days and seasonal pass-through revenue offset by lower SG&A and operational efficiencies, missing our estimates of 15.7%. Company reported highest ever deal win of \$1.5 billion.
- Management stated that the aspiration of 17-18% exit margin for FY24 will get pushed out by few quarters due to their commitment to invest in growth opportunities.
- We believe while the strong order inflows and ramp ups of deals would aid revenue growth, near term investments
  required for scaling up is likely to weigh on the margins and limit the earnings growth. Hence, we downgrade
  LTIMindtree to Hold with revised price target (PT) of a Rs 6,660 (increase in PT reflects roll forward to FY26 E EPS). At
  CMP, the stock trades at 32.6x/28.3x its FY25/26E EPS.

LTIMindtree's constant currency revenue growth of 0.7% q-o-q was largely in-line with our estimate of 0.9% q-o-q growth. The company reported revenue at \$1084 million, up 1.2% q-o-q/ 4.6% y-o-y. Revenue in rupee terms stood at Rs. 9017 crores up 1.2 q-o-q/4.6% y-o-y. Revenue growth was led by Manufacturing and Healthcare vertical but offset by weakness in Hi-tech, Retail and BF5I vertical. The company recorded the highest ever order inflow stood at \$1.5 billion for the quarter, up 21% y-o-y. EBIT margin declined ~60 bps q-o-q to 15.4% due to furloughs, lower working days and seasonal pass through revenue offset by lower \$G&A\$ and operational efficiencies, missing our estimates of 15.7%. Net profit stood at Rs.1169 crore, up 0.6%/ 16.8% q-o-q and y-o-y respectively missing our estimates of Rs. 1181 crore. Company recorded highest-ever order inflow stood of \$1.5 billion, up 21% y-o-y. Net Headcount additions declined 1061 taking the total headcount to 82,471. Attrition rate declined by 100 bps q-o-q to 14.2%. Utilisation (excluding trainees) improved to 87.4%, up 80 bps q-o-q. LTIMindtree reported in-line Q3 revenue growth in a seasonally soft quarter impacted by higher and wider than expected furloughs. Order inflow was robust being highest ever, while pipeline continues to stay strong. The company's strong order inflow and healthy deal pipeline has set the stage for medium-term growth. We believe while strong order inflows and ramp ups of deals would aid revenue growth as macro headwinds recede, the near-term investments required for scaling up as utilisation is at peak levels, is likely to weigh on the margins and limit the earnings growth. Hence, we downgrade LTIMindtree to Hold with revised price target (PT) of a Rs 6,660 (increase in PT reflects roll forward to FY26E EPS). At CMP, the stock trades at 32.6x/28.3x its FY25/26E EPS.

#### Key positives

- Highest ever order inflow stood of \$1.5 billion, up 21% y-o-y.
- LTM attrition declined by 100 bps q-o-q to 14.2%
- Utilisation (Excluding trainees) improved 80 bps q-o-q to 87.4%
- Manufacturing vertical grew 14.3% q-o-q

### Key negatives

- EBIT margin declined ~60 bps q-o-q to 15.4%.
- Retail and Hitech verticals declined 3.2%/3.0% q-o-q respectively.
- Net headcount additions declined 1061 taking the total headcount to 82,471.

#### **Management Commentary**

- Despite higher than anticipated seasonality in Q3, the company's strong order inflow and healthy deal pipeline has set the stage for medium-term growth.
- Q4 is expected to remain similar to the Q3, with continued challenging macroeconomic environment and delays in client decision making.
- Discretionary book is not getting refreshed as before and hence company is falling back on long term cost take out deals for growth.
- Most anticipated merger synergies are playing out well with a 30% increase in the overall pipeline except for macro headwind impact on discretionary spends.

 $\textbf{Revision in estimates} - \textbf{We} \ \textbf{have revised our estimates to factor Q3FY24} \ \textbf{performance and the soft near-term outlook}.$ 

#### Our Cal

Valuation – Downgrade to Hold with revised PT of Rs. 6,660: The company's strong order inflow and healthy deal pipeline has set the stage for medium-term growth. We expect sales/PAT CAGR of 10.5%/14.2% over FY23-26E. However, we believe while the strong order inflows and ramp ups of deals would assist in picking up growth momentum as macro headwinds recede, with utilisation at peak levels the near term investments required for scaling up is likely to weigh on the margins and limit the earnings growth. Hence, we downgrade LTIMindtree to Hold with revised price target (PT) of a Rs 6,660 (increase in PT reflects roll forward to FY26E EPS). At CMP, the stock trades at 32.6x/28.3x its FY25/26E EPS.

#### **Key Risks**

Rupee appreciation and/or adverse cross-currency movements. Contagion effect of banking crisis, macro headwinds and a possible recession in the US are likely to moderate the pace of technology spending.

Valuation (Consolidated)					Rs cr
Particulars	FY22	FY23	FY24E	FY25E	FY26E
Total Revenue	26,109	33,183	35,782	39,870	44,783
EBITDA margin %	20.1%	18.4%	18.3%	18.9%	19.1%
Adjusted Net Profit	3,948	4,408	4,766	5,701	6,568
% YoY growth		11.7	8.1	19.6	15.2
EPS (Rs)	133.4	149.0	161.1	192.6	222.0
PER (x)	47.0	42.1	39.0	32.6	28.3
P/BV (x)	12.8	10.4	8.7	7.6	6.7
EV/EBITDA	32.0	23.4	16.3	10.9	9.6
ROE (%)	30.2	27.2	24.3	24.9	25.3
ROCE (%)	34.9	34.6	31.3	31.4	33.7

Source: Company; Sharekhan estimates



# **Key result highlights**

- **Revenue growth:** Revenues stood at \$1084, up 0.7%/3.5% q-o-q and y-o-y respectively in constant currency (CC) which was largely in line with our estimates of 0.9% q-o-q CC revenue growth. Revenue in rupee terms stood at Rs. 9017 crores up 1.2 q-o-q/4.6% y-o-y. Revenue growth was led by Manufacturing and Healthcare vertical but offset by weakness in Hi-tech, Retail and BFSI vertical. Company registered highest ever order inflow stood at \$1.5 billion for the quarter, up 21% y-o-y.
- Margins: EBIT margin fell ~60 bps to 15.4% owing to furloughs, furloughs, lower working days, and seasonal passthrough revenue (-200bps) offset by SG&A benefit (+80bps) and operational efficiencies (+60 bps). Management stated that the aspiration of 17-18% exit margin will get pushed out by few quarters due to their commitment to invest in growth opportunities.
- **Vertical-wise performance:** In terms of verticals, Manufacturing and Healthcare vertical was up 14.3% /0.8% q-o-q respectively while Hi-tech, Retail and BFSI vertical which declined 3.0%/3.2% and 1.7% q-o-q respectively. The company continues to see challenges in BFS while insurance remains resilient. Company is seeing demand for services related to data in the travel, transport, and hospitality vertical.
- **Geography-wise performance:** In terms of geographies, North America/Europe declined 0.2%/4.5%, respectively while ROW grew 14.1% q-o-q, respectively.
- **People Metrics:** LTM attrition declined by 100 bps q-o-q to 14 .2%. Net additions declined 1061 q-o-q taking the total headcount to 82,471. Utilisation (excluding trainees) improved to 87.4% up 80bps q-o-q. The company onboarded 500 plus freshers this quarter and plan to continue hiring on a relatively real time basis. The company has trained over 10,000 employees on Gen AI to stay ahead in the ever- evolving AI landscape.
- Client Metrics: LTIMindtree added 23 new clients while the number of active clients increased to 739 from 737. Client additions in \$50 million+, \$20 million+ and \$10 million+ category declined by -2/-1 and -1 q-o-q respectively while \$5 million + category increased by 3 q-o-q. Top 5, Top 10, Top 20 and Top 40 client revenues grew 3.4%/3.7%/2.3% and 2.3% q-o-q respectively.
- **Strong Cash Conversion:** The operating cash flow to PAT was 155.7% in Q3FY24 versus 92.1% in Q2FY24 on account of strong collections. Free cash flow to PAT has shown a strong improvement to 143.7% in Q3FY24 versus to 75.1% in O2FY24.



Results (Consolidated) Rs cr

Particulars	Q3FY24	Q3FY23	Q2FY24	YoY (%)	QoQ (%)
Revenues In USD (mn)	1,084	1,047	1,076	3.5	0.8
Revenues In INR	9,017	8,620	8,905	4.6	1.2
Direct Costs	5,633	5,472	5,681	2.9	-0.8
Other Expenses	1,148	1,019	921	12.7	24.5
Sub contracting cost	652	754	672	-13.6	-3.0
EBITDA	1,585	1,375	1,631	15.3	-2.8
Depreciation & amortization	199	178	208	11.7	-4.4
EBIT	1,386	1,197	1,423	15.8	-2.6
Finance Costs	61	38	47	60.2	29.1
Other Income	220	152	143	44.6	53.3
РВТ	1,545	1,311	1,519	17.9	1.7
Tax Provision	375	310	357	21.1	5.2
Net profit	1,169	1,001	1,162	16.8	0.6
Adjusted net profit	1,169	1,001	1,162	16.8	0.6
EPS (Rs)	39.2	40.1	38.9	-2.3	0.8
Margin (%)					
EBITDA	17.6	15.9	18.3	163	-74
EBIT	15.4	13.9	16.0	149	-61
NPM	13.0	11.6	13.0	136	-8
Tax rate	24.3	23.6	23.5	66	80

Source: Company; Sharekhan Research

Operating metrics Rs cr

Daniel and annual	Revenues	Revenues Contribution \$		th (%)	CC growth (%)		
Particulars	(\$ mn)	(%)	Q-o-Q %	Y-o-Y %	Q-o-Q %	Y-o-Y %	
Revenues (\$ mn)	1,084	100	0.8	3.5	0.7	3.1	
Geographic mix							
North America	788	72.7	-0.2	4.1			
Europe	157	14.5	-4.5	0.8			
ROW	139	12.8	14.1	3.5			
Industry verticals							
BFSI	386	35.6	-1.7	-1.4			
Hi-tech, Media & Entertainment	248	22.9	-3.0	0.5			
Manufacturing & Resource	220	20.3	14.3	20.1			
Retail, CPG, Travel, Transportation & Hospitality	159	14.7	-3.2	0.1			
Health, Life Sciences & Public Services	70	6.5	0.8	6.8			

Source: Company; Sharekhan Research



#### **Outlook and Valuation**

# ■ Sector View – Macro heading winds bottoming out coupled with better earnings visibility

We anticipate growth momentum to return in FY25 aided by lower base coupled with easing sector headwinds. Though, IT sector has already outperformed the Nifty last year, we expect overall outperformance in CY24 as well driven by receding headwinds and better earnings visibility

# ■ Company Outlook – Superior execution likely to drive outperformance

We believe that LTIM's prudent strategies along with an efficient sales-force would lead to market share gains in large accounts and new deal wins. Hence, we expect LTIM to deliver industry-leading revenue growth in the long term on account of consistent large deal wins and deal pipeline, higher digital mix, prudent account mining strategies and a marquee client base. Further, LTIM's sharp focus on bringing new-age disruptive technologies and leveraging of platforms (in-house and external) would help it transform the core business of enterprises on a large scale.

# ■ Valuation – Downgrade to Hold with revised PT of Rs. 6,660

The company's strong order inflow and healthy deal pipeline has set the stage for medium-term growth. We expect sales/PAT CAGR of 10.5%/14.2% over FY23-26E. However, we believe while the strong order inflows and ramp ups of deals would assist in picking up growth momentum as macro headwinds recede, with utilisation at peak levels the near term investments required for scaling up is likely to weigh on the margins and limit the earnings growth. Hence, we downgrade LTIMindtree to Hold with revised price target (PT) of a Rs 6,660 (increase in PT reflects roll forward to FY26E EPS). At CMP, the stock trades at 32.6x/28.3x its FY25/26E EPS.

#### **Peer valuation**

	СМР	O/S	MCAP -	P/E	(x)	EV/EBI	TDA (x)	P/B\	/ (x)	RoE	(%)
Particulars	(Rs / Share)	Shares (Cr)	(Rs Cr)	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E
LTIM	6,278	30	152586	39.0	31.3	16.3	10.5	8.7	7.6	24.3	25.9
Infosys	1,640	415	6,80,322	27.8	23.7	18.0	15.6	4.6	4.4	30.3	33.7
TCS	3,884	366	14,21,450	30.5	27.5	21.2	18.9	13.5	13.2	47.5	48.5

Source: Company, Sharekhan estimates



# **About company**

L&T Infotech (LTI) and Mindtree Ltd (Mindtree), on May 06, 2022, announced the proposal to merge Mindtree into LTI through a scheme of amalgamation as approved by the respective boards of the companies. LTI and Mindtree have merged into LTIMindtree in Nov 2022, becoming the country's fifth largest provider of IT services by market capitalisation and sixth largest IT company revenue.

#### **Investment theme**

A multitude of factors such as strong execution capabilities, a dynamic sales team, accelerating revenue contribution from its digital business, leverage of domain experience, solid top account mining, and healthy deal wins have been helping LTIMindtree to outpace the average industry growth rate. Further, the gradual increase in digital deal sizes along with high volume digital deals and migration of the legacy business has helped the company grow at a rapid pace compared to its peers. We believe the sharpened focus on large account mining and new client additions augurs well for LTIMindtree to deliver above-industry average revenue growth.

# **Key Risks**

Rupee appreciation or/and adverse cross-currency movements, slower-than-expected technology spends by customers and a loss of any large clients would affect earnings.

#### **Additional Data**

#### Key management personnel

Debashis Chatterjee	MD & CEO
Nachiket Deshpande	WTD & COO
Sudhir Chaturvedi	WTD & President, Markets
Vinit Teredesai	CFO

Source: Company Website

#### **Top 10 shareholders**

Sr. No.	Holder Name	Holding (%)
1	Life Insurance Corp of India	3.54
2	UTI Asset Management Co Ltd	1.71
3	Vanguard Group Inc	1.23
4	BlackRock Inc	1.06
5	SBI Funds Management Ltd	0.79
6	Aditya Birla Sun Life Asset Manage	0.58
7	Axis Asset Management Co Ltd	0.52
8	Tata Asset Management Pvt Ltd	0.47
9	ICICI Prudential Asset Management	0.42
10	Norges Bank	0.42

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

# **Understanding the Sharekhan 3R Matrix**

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
<b>Right Quality</b>	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/ weak realisation environment resulting in margin pressure and detoriating balance sheet
<b>Right Valuation</b>	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research



#### **DISCLAIMER**

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/ material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. CIN): - U99999MH1995PLC087498. Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-6115000.

Correspondence/Administrative Office: Gigaplex IT Park, Unit No 1001, 10th Floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai – 400 708. Tel: 022 61169000 / 61150000, Fax No. 61169699.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669.

Compliance Officer: Ms. Binkle Oza; Tel: 022-62263303; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022-41523200 / 022-69920600.